Literature DB >> 20979053

Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms.

Benjamin Goeppert1, Peter Schmezer, Céline Dutruel, Christopher Oakes, Marcus Renner, Marco Breinig, Arne Warth, Monika Nadja Vogel, Michel Mittelbronn, Arianeb Mehrabi, Georg Gdynia, Roland Penzel, Thomas Longerich, Kai Breuhahn, Odilia Popanda, Christoph Plass, Peter Schirmacher, Michael André Kern.   

Abstract

UNLABELLED: The A kinase anchor protein 12 (AKAP12) is a central mediator of protein kinase A and protein kinase C signaling. Although AKAP12 has been described to act as a tumor suppressor and its expression is frequently down-regulated in several human malignancies, the underlying molecular mechanisms responsible for the AKAP12 reduction are poorly understood. We therefore analyzed the expression of AKAP12 and its genetic and epigenetic regulatory mechanisms in human hepatocarcinogenesis. Based on tissue microarray analyses (n = 388) and western immunoblotting, we observed a significant reduction of AKAP12 in cirrhotic liver (CL), premalignant lesions (DN), and hepatocellular carcinomas (HCCs) compared to histologically normal liver specimens (NL). Analyses of array comparative genomic hybridization data (aCGH) from human HCCs revealed chromosomal losses of AKAP12 in 36% of cases but suggested additional mechanisms underlying the observed reduction of AKAP12 expression in hepatocarcinogenesis. Quantitative methylation analysis by MassARRAY of NL, CL, DN, and HCC tissues, as well as of various tumorigenic and nontumorigenic liver cell lines revealed specific hypermethylation of the AKAP12α promoter but not of the AKAP12β promoter in HCC specimens and in HCC cell lines. Consequently, restoration experiments performed with 5-aza-2'deoxycytidine drastically increased AKAP12α mRNA levels in a HCC cell line (AKN1) paralleled by AKAP12α promoter demethylation. As hypermethylation is not observed in CL and DN, we investigated microRNA-mediated posttranscriptional regulation as an additional mechanism to explain reduced AKAP12 expression. We found that miR-183 and miR-186 are up-regulated in CL and DN and are able to target AKAP12.
CONCLUSION: In addition to genetic alterations, epigenetic mechanisms are responsible for the reduction of the tumor suppressor gene AKAP12 in human hepatocarcinogenesis.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20979053     DOI: 10.1002/hep.23939

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  35 in total

Review 1.  The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-11-21       Impact factor: 7.527

2.  miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.

Authors:  X Zhu; H Shen; X Yin; L Long; C Xie; Y Liu; L Hui; X Lin; Y Fang; Y Cao; Y Xu; M Li; W Xu; Y Li
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

3.  miR-709 up-regulated in hepatocellular carcinoma, promotes proliferation and invasion by targeting GPC5.

Authors:  Tonggang Liu; Xuezhong Zhang; Kaihui Sha; Xianxian Liu; Liguo Zhang; Bangmao Wang
Journal:  Cell Prolif       Date:  2015-03-27       Impact factor: 6.831

4.  Primate fetal hepatic responses to maternal obesity: epigenetic signalling pathways and lipid accumulation.

Authors:  Sobha Puppala; Cun Li; Jeremy P Glenn; Romil Saxena; Samer Gawrieh; Amy Quinn; Jennifer Palarczyk; Edward J Dick; Peter W Nathanielsz; Laura A Cox
Journal:  J Physiol       Date:  2018-04-06       Impact factor: 5.182

5.  Aberrant TIG1 methylation associated with its decreased expression and clinicopathological significance in hepatocellular carcinoma.

Authors:  Xi-Hua Chen; Wen-Guang Wu; Jian Ding
Journal:  Tumour Biol       Date:  2013-09-05

6.  miR-186 inhibits cell proliferation of prostate cancer by targeting GOLPH3.

Authors:  Xing Hua; Yu Xiao; Wenhai Pan; Meiyun Li; Xiaoxiao Huang; Zexiao Liao; Qi Xian; Lina Yu
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

7.  DNA methylation-mediated repression of miR-941 enhances lysine (K)-specific demethylase 6B expression in hepatoma cells.

Authors:  Pei-Pei Zhang; Xiang-Ling Wang; Wei Zhao; Bing Qi; Qian Yang; Hai-Ying Wan; Ze-Yu Shuang; Min Liu; Xin Li; Shengping Li; Hua Tang
Journal:  J Biol Chem       Date:  2014-07-21       Impact factor: 5.157

8.  Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.

Authors:  Benjamin Goeppert; Christina Ernst; Constance Baer; Stephanie Roessler; Marcus Renner; Arianeb Mehrabi; Mohammadreza Hafezi; Anita Pathil; Arne Warth; Albrecht Stenzinger; Wilko Weichert; Marion Bähr; Rainer Will; Peter Schirmacher; Christoph Plass; Dieter Weichenhan
Journal:  Epigenetics       Date:  2016-09-03       Impact factor: 4.528

9.  Epigenetic regulation of miR-34a expression in alcoholic liver injury.

Authors:  Fanyin Meng; Shannon S Glaser; Heather Francis; Fuquan Yang; Yuyan Han; Allison Stokes; Dustin Staloch; Jennifer McCarra; Jingang Liu; Julie Venter; Haiying Zhao; Xiuping Liu; Taylor Francis; Scott Swendsen; Chang-Gong Liu; Hidekazu Tsukamoto; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2012-07-25       Impact factor: 4.307

10.  Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment.

Authors:  Thananya Jinato; Natthaya Chuaypen; Witthaya Poomipak; Kesmanee Praianantathavorn; Jarika Makkoch; Rattanaporn Kiatbumrung; Kanisa Jampoka; Pisit Tangkijvanich; Sunchai Payungporn
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.